More about the role of the HGF/MET pathway in acquiring resistance to targeted drugs in the treatment of lung and colon cancer, as well as melanoma, can be found in the review by Della Corte [42] et al. The aforementioned results argue for further evaluation of this protein as a predictive marker of melanoma response to targeted therapy. The gene discussed is MET; the disease is melanoma.